does lumateperone cost about $1,800 a month in the us
“Luma teperone runs about $1,800 a month.”
a host said on Psychopharmacology and Psychiatry Updates, 2026-11-18, at 09:27. hear it in context →
the episode: Which Adjunctive Antipsychotic Is Best for Major Depression? (at 09:27). we link the show's own page; we do not re-host audio.
first, the part that holds
the host's figure holds. Lumateperone is a once-daily capsule, and in the US a month of it costs roughly $1,700 before insurance in every federal record we checked, so "about $1,800" is close. A figure of $18 a month is about a hundredth of the drug's price.
what we found when we went and looked
The federal survey of what retail pharmacies pay for drugs (the national average drug acquisition cost, or NADAC) priced the 42 mg capsule at $57.23 each in the week of 2026-11-18. The label dose is one capsule a day, so a 30-day supply comes to about $1,717. Medicare Part D data match that. Gross spending averaged $1,686 per claim in 2024, $1,669 in 2025 and $1,715 in the first quarter of 2026, and the 2024 claims averaged about 30 capsules each. The host's $1,800 is about 5% above these figures, which "about" covers. The guest's $18 is about 1% of the real price, so the two figures do conflict.
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| lumateperone costs about $1,800 per month in the US | confirmed | Pharmacy acquisition cost (NADAC) for the 42 mg capsule was $57.23406 each, effective 2026-11-18. At one capsule a day that is about $1,717 for 30 days. Medicare Part D gross spending averaged $1,714.75 per claim in Q1 2026 and $1,668.90 per claim across 2025. Both are within about 5% of $1,800. Neither figure includes manufacturer rebates or what a patient pays at the counter. [1][2][3][4] |
| the $1,800 figure conflicts with the guest's earlier figure of $18 a month | confirmed | Every federal measure we read puts a month of lumateperone near $1,700 before insurance. $18 is about 1% of that, so it cannot be the drug's list or acquisition cost. We did not read the guest's own words. If the guest meant a copay after insurance, the federal data cannot test that, but it would still be a different number from the drug's cost. [1][2][3] |
| a month means one capsule a day, so about 30 capsules | confirmed | The FDA label says: 'The recommended CAPLYTA dosage is 42 mg administered orally once daily with or without food.' The lower strengths (21 mg and 10.5 mg) are for people taking certain interacting drugs or with liver impairment. In 2024 Medicare data, claims averaged about 30.1 capsules each (4,786,012 capsules over 159,224 claims). Per-capsule prices are nearly the same at every strength (about $57). [2][3][4] |
| the price has been rising | confirmed | Medicare Part D average spending per capsule rose from $45.58 in 2020 to $56.10 in 2024, a compound annual growth rate of 5.3% per CMS. The per-capsule acquisition cost for the 42 mg strength went from $54.60 (effective 2025-12-17) to $57.33 (2026-01-02) and has stayed near $57.2 since. That suggests a list-price increase in January 2026, though NADAC is a pharmacy survey, not a list price. [1][2] |
both directions
for the speaker: Two independent federal datasets land near $1,700 for a 30-day supply: the CMS weekly pharmacy acquisition-cost survey ($57.23 per 42 mg capsule as of 2026-11-18) and Medicare Part D claims ($1,714.75 average gross spending per claim in Q1 2026). Both put the host within about 5%. The FDA label gives one capsule a day as the standard dose, so a month means about 30 capsules. Medicare claims average about 30 capsules each. Per-capsule spending has risen every year since 2020, so a figure quoted in late 2026 is unlikely to be too high.
against: "About $1,800" is about $80 to $100 above both federal measures, so the host rounded slightly up. Neither federal number is what most people pay. Medicare Part D gross spending and NADAC both exclude confidential manufacturer rebates, which can make the plan's net cost much lower. Patients with insurance or manufacturer copay help often pay far less out of pocket. If the guest's $18 was a copay, both speakers could be describing real but different numbers. In that case the clash is about which cost each was talking about, not a mistake by either one.
what this cannot say
NADAC measures what retail pharmacies pay to buy the drug, not the manufacturer's list price and not the cash price at the counter. Cash prices at pharmacies usually run higher. Medicare Part D spending is gross spending before rebates, and the 2026 figures are preliminary quarterly data that CMS revises. Neither dataset shows net prices after rebates or any one person's out-of-pocket cost. We did not hear the guest's original statement or its context, so we cannot say what the $18 referred to. Our monthly figure assumes 30 capsules at the standard dose and rounds to whole dollars.
sources, each one fetched and read
- Centers for Medicare & Medicaid Services, National Average Drug Acquisition Cost (NADAC) weekly file, data.medicaid.gov, lumateperone 42 mg capsule (NDC 72060014240), as of 2026-11-18 What we read there: Lumateperone 42 mg capsule: NADAC per unit $57.23406, pricing unit EA, effective date 2026-11-18. Prior rate $57.24035, effective 2026-10-21. Fetched 2026-11-18 (HTTP 200). https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc_description&conditions[0][value]=CAPLYTA 42%25&conditions[0][operator]=LIKE&sorts[0][property]=as_of_date&sorts[0][order]=desc&limit=5
- Centers for Medicare & Medicaid Services, Medicare Part D Spending by Drug (annual), data.cms.gov, lumateperone tosylate, 2020-2024 What we read there: 2024: total spending $268,479,293; 4,786,012 dosage units; 159,224 claims; average spending per dosage unit $56.10; average spending per claim $1,686.17. 2020 per-unit average was $45.58; compound annual growth rate 2020-2024 was 5.3%. Fetched 2026-11-18 (HTTP 200). https://data.cms.gov/data-api/v1/dataset/7e0b4365-fd63-4a29-8f5e-e0ac9f66a81b/data?filter[Gnrc_Name]=Lumateperone Tosylate
- Centers for Medicare & Medicaid Services, Medicare Quarterly Part D Spending by Drug, data.cms.gov, lumateperone tosylate, 2025 and 2026 Q1 What we read there: 2025 (Q1-Q4): 210,435 claims, total spending $351,195,165, average spending per claim $1,668.90. 2026 (Q1): 63,792 claims, total spending $109,387,497, average spending per claim $1,714.75. Fetched 2026-11-18 (HTTP 200). https://data.cms.gov/data-api/v1/dataset/4ff7c618-4e40-483a-b390-c8a58c94fa15/data?filter[Gnrc_Name]=Lumateperone Tosylate
- US Food and Drug Administration, lumateperone capsules prescribing information, DailyMed (National Library of Medicine), setid db730b06-6351-47fd-8183-e61e61bbead5 What we read there: 'The recommended ... dosage is 42 mg administered orally once daily with or without food.' 'Dose titration is not needed.' The 21 mg and 10.5 mg strengths are for use with moderate or strong CYP3A4 inhibitors or with moderate or severe hepatic impairment. Fetched 2026-11-18 (HTTP 200). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db730b06-6351-47fd-8183-e61e61bbead5
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam